Autolus reports Q1 2024 net loss of $52.7M; cash $758.5M; obe-cel PDUFA Nov 16

Autolus Therapeutics plc

2024-Q1 EPS reported -$0.24 revenue$10,091,000

Net loss $52.7M ($0.24 diluted EPS) vs $39.8M loss year ago; license revenue $10.1M.
Cash $758.5M at March 31, 2024, up from $239.6M Dec 31, after $350M offering and BioNTech financing.
Obe-cel BLA under FDA review; PDUFA target action date Nov 16, 2024; MAA accepted by EMA.
First two patients enrolled in SLE Phase 1 (CARLYSLE); initial data expected end of 2024.
BioNTech strategic collaboration ($50M upfront, up to $582M milestones) and $200M private placement; Mike Bonney appointed Chairman.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Autolus Therapeutics plc reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its operational and financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Autolus Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001730463-24-000059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.